A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
From stem cell research to spinal implants, here are three studies Becker's reported on since Jan. 15.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback